Organo-metal compound seen killing cancer cells from inside

February 13, 2017
Credit: University of Warwick

Researchers have witnessed—for the first time—cancer cells being targeted and destroyed from the inside, by an organo-metal compound discovered by the University of Warwick.

Professor Peter J. Sadler, and his group in the Department of Chemistry, have demonstrated that Organo-Osmium FY26—which was first discovered at Warwick—kills cancer cells by locating and attacking their weakest part.

This is the first time that an Osmium-based compound – which is fifty times more active than the current cancer drug cisplatin—has been seen to target the disease.

Using the European Synchrotron Radiation Facility (ESRF), researchers analysed the effects of Organo-Osmium FY26 in ovarian cancer cells—detecting emissions of X-ray fluorescent light to track the activity of the compound inside the cells.

Looking at sections of cancer cells under nano-focus, it was possible to see an unprecedented level of minute detail. Organelles like mitochondria, which are the 'powerhouses' of cells and generate their energy, were detectable.

In cancer cells, there are errors and mutations in the DNA of mitochondria, making them very weak and susceptible to attack.

FY26 was found to have positioned itself in the mitochondria—attacking and destroying the vital functions of cancer cells from within, at their weakest point.

Researchers were also able to see natural metals which are produced by the body – such as zinc and calcium—moving around the cells. Calcium in particular is known to affect the function of cells, and it is thought that this naturally-produced metal helps FY26 to achieve an optimal position for attacking cancer.

More than half of all cancer chemotherapy treatments currently use platinum compounds, which were introduced nearly 40 years ago, so there is a need to explore the benefits which other precious metals could bring.

Although this research was conducted on , the ground-breaking results are applicable to a wider range of cancers.

FY26 has been shown to be more selective between and cancer cells than cisplatin—having a greater effect on cancer cells than on healthy ones.

Professor Sadler comments that this research could lead to new cancer treatments:

"Cancer drugs with new mechanisms of actions which can combat resistance and have fewer side-effects are urgently needed.

"The advanced nano-focused X-ray beam at ESRF has not only allowed us to locate the site of action of our novel Organo-Osmium FY26 candidate drug in at unprecedented resolution, but also study the movement of natural metals such as zinc and calcium in cells. Such studies open up totally new approaches to drug discovery and treatment"

Professor Sadler's group, including research fellows Dr Carlos Sanchez and Dr Isolda Romero Canelon, gained their results with Dr Peter Cloetens and colleagues at the ESRF in Grenoble, France—a powerful synchrotron source which emits extremely powerful X-ray beams.

Dr Peter Cloetens comments on the process:

"These kinds of experiments are normally performed using bigger doses than what would be done in real life or on a coarse scale that does not provide a clear picture of the processes that take place. On the new nano-imaging ID16A beamline, however, by combining a very tight focus and high flux, we could get a real picture of where the drug goes in a single cell using real-life pharmacological doses."

Explore further: Cancer drug 49 times more potent than Cisplatin

More information: Carlos Sanchez-Cano et al. Synchrotron X-Ray Fluorescence Nanoprobe Reveals Target Sites for Organo-Osmium Complex in Human Ovarian Cancer Cells, Chemistry - A European Journal (2017). DOI: 10.1002/chem.201605911

Related Stories

Cancer drug 49 times more potent than Cisplatin

July 7, 2015
Tests have shown that a new cancer drug, FY26, is 49 times more potent than the clinically used treatment Cisplatin.

New drug raises potential for cancer treatment revolution

March 21, 2014
(Medical Xpress)—A revolution in cancer treatment could soon be underway following a breakthrough that may lead to a dramatic improvement in cancer survival rates. A new study at the University of Warwick, published today ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.